Selecta Biosciences Культура компании

Dr. Werner Cautreels, Ph.D., serves as the Chief Executive Officer of Abbott Products SA. Dr. Cautreels has been the Chief Executive Officer and President of Selecta Biosciences, Inc. since July 2010. He joined Selecta Biosciences, Inc. in 2010. He served as Global Chief Executive Officer of Solvay Pharmaceuticals S.A at Abbott Products, Inc. since January 2005. He served as the Global Chief Executive Officer of Solvay Pharmaceuticals S.a.r.l. He served as General Manager of the Pharmaceuticals Sector for Solvay North America, LLC. He served as General Manager of the Pharmaceuticals Sector for Solvay SA. Dr. Cautreels served as Global Head of Research and Development at Solvay Pharmaceuticals S.A. He served at Nycomed Amersham Ltd., Sterling Winthrop and Sanofiin held a variety of R&D management positions in Europe and the United States. He serves as Chairman of Solvay Pharmaceuticals Inc., Solvay Pharmaceuticals GmbH, Innogenetics NV, Laboratoires Fournier and BTG Pharma. He served as the Chairman of Selecta Biosciences, Inc. until 2018. He has been an Independent Director of Galapagos NV since June 2, 2009. Dr. Cautreels has been a Director of Innogenetics NV since 1999. He serves as a Director of Solvay Pharmaceuticals SARL, Solvay Pharmaceuticals BV, Solvay pharmaceuticals SA, Solvay Pharma SA and Fournier Industrie et Sante. He has been a Director of Selecta Biosciences, Inc. since July 2010. He serves as a Member of Scientific Advisory Board of ArQule Inc. and served as its Director from September 1999 to April 12, 2006. He served as a Director of Seres Therapeutics, Inc. since October 7, 2014 until June 14, 2016. He served as a Director of ArQule Inc., from September 1999 to April 13, 2006. Dr. Cautreels was the President of the Belgian-Luxemburg Chamber of Commerce for Russia and Belarus. He received his Bachelor and Master of Science in Chemistry, Advanced Managmenet Programme from Harvard and Ph.D. in Chemistry from University of Antwerp, Belgium. He holds Master degree in Industrial Management from Catholic University of Louvain.

Mr. Earl E. Sands, also known as Skip, M.D., has been the Chief Medical Officer of Selecta Biosciences, Inc. since July 2015. Mr. Sands oversees all clinical development and regulatory activities for the Selecta Biosciences, as Selecta rapidly advances its product candidates in and toward human clinical trials for a range of diseases, including refractory gout, gene therapy, smoking cessation, human papillomavirus (HPV) associated cancers and others. He is a seasoned biopharmaceutical executive with experience advancing early stage R&D programs successfully through clinical development and product commercialization. Mr. Sands served as Vice President of Research and Development of AbbVie Products, LLC since March 2007. He has expertise in developing, advancing and commercializing products for a wide range of indications. He has over two decades of experience and has a professional career spanned the corporate biopharmaceutical, academic and private medical practice worlds. During his career, he led and contributed to numerous clinical programs from IND through sNDA/sBLA/MAA, including programs in neuroscience, cardio-metabolic, vaccines, cancer and others. Mr. Sands served as CMO of Targacept from 2014 to 2015 and Plasma Surgical from 2013 to 2014. From 2011 to 2013, he was a Consultant to biotechnology, pharmaceutical and health care companies and led protocol development and execution for Phase 1-4 studies in a number of areas, including women's and men's health, oncology, neuroscience and gastroenterology. From 2003 to 2011, Mr. Sands served with Solvay Pharmaceuticals/Abbott Laboratories (following its acquisition of Solvay) in a series of roles of increasing responsibility culminating as Executive Vice President, Market Access and including Senior Vice President of Research and Development. Earlier in his career, he worked with Procter & Gamble Pharmaceuticals, where he was a Managing Partner in a medical practice. He earned his Medical Doctor Degree from Hahnemann University School of Medicine in Philadelphia, PA and has completed courses in the Executive MBA program at Emory University in Atlanta, GA. He received his B.A. in Premedical Sciences from Lehigh University.

Dr. Omid C. Farokhzad, M.D., serves as a Principal of Dynamics Group, LLC and serves as its Member of Advisory Board. Dr. Farokhzad is a Co-founder of BIND Therapeutics, Inc. He is a Co-founder of Selecta Biosciences, Inc. and has been its Chairman since December 31, 2017 and Member of the Scientific Advisory Board since 2008 and served as its Vice Chairman. Dr. Farokhzad is a Co-founder of Blend Therapeutics, Inc. and serves as its Member of the Scientific Advisory Board since 2006. Dr. Farokhzad served as a Member of the Scientific Advisory Board of BIND Therapeutics, Inc. since 2006. He served as a Director of Blend Therapeutics, Inc. since 2006 until May 28, 2014. He serves as an Associate Professor at Harvard Medical School (HMS) and a physician-scientist in the Department of Anesthesiology at Brigham and Women's Hospital (BWH). His research group is focused on developing novel nanotechnologies for medical applications. He has pioneered the application of micro- and nanotechnology for a myriad of clinical applications. Dr. Farokhzad has authored more than 100 papers and is an inventor of more than 125 issued and pending patents worldwide. Dr. Farokhzad was elected to the College of the Fellows of the American Institute of Medical and biological Engineering. He was among the Nano50 winners by NASA Nanotech Briefs, which awards the most innovative people and design ideas that will revolutionize nanotechnology and was among the 15 recipients across all industries to receive the All Star Distinguished Achievement Award from the Mass High Tech Journal for his contributions to the Life Sciences industry. He has been a Director of Selecta Biosciences, Inc. since 2007. He serves as a Director at Tarveda Therapeutics, Inc. He was an Ernst & Young Entrepreneur of the Year awardee for the Northeast Region. In 2013 the Boston Globe selected him among the top 12 innovators in Massachusetts and the Boston Business Journal selected him as one of the 2 innovator awardees for the Champions in Healthcare. He completed his post-doctoral clinical and research trainings, respectively, at the BWH and HMS and MIT in the laboratory of Dr. Robert Langer. Dr. Farokhzad holds an M.D. and M.A. from Boston University School of Medicine and an MBA from Massachusetts Institute of Technology.

Mr. Peter Keller, M.Sci has been the Chief Business Officer of Selecta Biosciences, Inc since February 2011 and served as its Vice President of Business Development and Alliance Management. Mr. Keller joined Selecta Biosciences from Abbott Laboratories in February 2011. After the acquisition of Solvay Pharmaceuticals by Abbott Laboratories, he led the integration process for five R&D and Manufacturing facilities in Europe. Mr. Keller served as Vice President for Business Development and Alliance Management at Solvay Pharmaceuticals where he negotiated license and acquisition agreements in various therapeutic areas such as vaccines, neurology and cardiology. He was the lead negotiator for the $1.5 billion fenofibrate alliance between Solvay Pharmaceuticals and Abbott Laboratories. Mr. Keller also gained almost ten years of experience in management consulting with McKinsey & Company and Simon Kucher and Partners. He has worked with five of the ten biggest pharmaceutical companies and specialized in marketing strategy and M&A transactions. Mr. Keller holds a M.Sci. in Industrial Engineering and Management from the University of Karlsruhe, Germany.

Dr. Ulrich H. von Andrian, M.D., Ph.D. has been an Advisor of PureTech Health plc since October 13, 2016. Dr. von Andrian-Werburg has been the Mallinckrodt Professor of Immunopathology at Harvard Medical School since 2011. Dr. von Andrian served as Edward Mallinckrodt Jr. Professor of Immunopathology at Harvard Medical School since 2006. During the past 26+ years, he has been conducting basic research in immunology using a broad range of molecular, cellular and whole animal approaches. A major scientific focus has been on the molecular mechanisms of immune cell migration and homing in lymphoid and non-lymphoid tissues using intravital microscopy techniques. He has knowledge of basic exploration of immune responses to exogenous and endogenous challenges such as infections, tumors and immune diseases. Using in vivo microscopic imaging technologies developed in his laboratory, Dr. von Andrian has identified how different immune cells migrate and communicate in living tissues and how immunomodulatory drugs can be designed to control and modify these events. He co-founded Selecta Biosciences to apply these insights to the development of rationally engineered immunobiologics for the treatment and prevention of human diseases. Dr. von Andrian is the Co-Founder of Selecta Biosciences, Inc. and serves as its Co-Chair of the Scientific Advisory Board. He has been a Member of Scientific Advisory Board at Morphic Rock Therapeutic, Inc. since 2006. He serves as Member of Scientific Advisory Board at Moderna Therapeutics, Inc. He serves as Member of Scientific Advisory Council at Cancer Research Institute, Inc. He serves as Member of Scientific Advisory Board at Tarveda Therapeutics, Inc. (formerly Blend Therapeutics, Inc.). He served as Member of Scientific Advisory Board at DNIB Unwind, Inc. He has been Program Leader, Basic Immunology and Member, Steering Committee, Ragon Institute at MGH, MIT and Harvard, Cambridge, MA since 2013. Dr. von Andrian is a Member of the European Academy of Sciences and several professional societies from which he has received awards for outstanding research, including the Amgen Outstanding Investigator Award, the Henry Pickering Bowditch Award, the BD Biosciences Investigator Award and the Eugene Landis Award. From 1988 to 1989, he was Internship, Dept. of Surgery, Zentralklinikum Augsburg, Germany; Dept. of Neurology, Univ. of Michigan, Ann Arbor, MI; and Medizinische Klinik I, Klinikum Gro???hadern, Munich, Germany. He was a Visiting Scholar, Dept. of Applied Mechanics and Engineering Sciences, UCSD, La Jolla, CA from 1989 to 1992. From 1994 to 1999, he was Assistant Professor of Pathology, Harvard Medical School and Junior Investigator at CBR Institute for Biomedical Research, Boston, MA. From 1999 to 2003, he was Associate Professor of Pathology, Harvard Medical School and Investigator at CBRI. From 2003 to 2011, he was Professor of Pathology at Harvard Medical School and Senior Investigator at CBRI. He was a Postdoctoral Fellow at La Jolla Institute for Experimental Medicine, La Jolla, CA from 1989 to 1992. He has been on the Editorial Boards of Journal of Experimental Medicine since 2002, Faculty of 1000 since 2003, Current Immunology Reviews since 2004, Associate Editor, Immunity since 2005, Journal of Vascular Research since 2007, The Open Microbiology Journal since 2007, The Year in Immunology (NY Academy of Sciences) since 2007 and Cell since 2009. He served on the Editorial Boards of Microcirculation from 1999 to 2004, American Journal of Physiology: Heart and Circulatory Physiology from 1999 to 2000 and Board of Reviewing Editors, Science from 2008 to 2010. He has been a Member of Microcirculatory Society (MCS) since 1994, American Association of Immunologists (AAI) since 1998, North American Vascular Biology Organization (NAVBO) since 1998, Elected Member of American Association of University Pathologists (Pluto Society) since 2000, American Society for Investigative Pathology (ASIP) since 2002, Elected Member of European Academy of Sciences since 2002, The American Society for Cell Biology (ASCB) since 2004 and American Physiological Society (APS) since 2005. His postdoctoral research involved the development of intravital microscopy techniques that led to the discovery of the multi-step leukocyte adhesion cascade in vivo. After a second postdoctoral fellowship in the laboratory of Dr. Eugene C. Butcher at Stanford University from 1992 to 1993, Dr. von Andrian joined the Faculty of Harvard Medical School in 1994. He holds an M.D. from Ludwig-Maximillians University (Germany) in 1989, where he also conducted doctorate research on blood-brain barrier dysfunction following brain injury. He received Phd in Neurology/Neurosurgery from Ludwig-Maximilians Univ. Munich, Germany in 1992.

Mr. Stephen Smolinski has been Chief Commercial Officer at Selecta Biosciences, Inc. since October 26, 2017. Mr. Smolinski leads the development of commercial plans for Selecta's product candidates. Mr. Smolinski served as Senior Director of Marketing at Savient Pharmaceuticals, Inc. since April 2011. Mr. Smolinski's experience includes nearly 25 years of diverse experience in health care and the biopharmaceutical industry, including leadership positions in marketing, sales and global strategic marketing. He held positions at Centocor, Ortho Biotech, Johnson & Johnson, Savient Pharmaceuticals, Inc, Bristol-Myers Squibb and Roche-Genentech. He served as Vice President and Head of Sanofi/Genzyme's North American Rheumatology Business Unit, where he led the development of commercialization plans for the rheumatoid arthritis medicine KEVZARA??. He served as Group Vice President of Immunology & Inflammation, Global Strategic Unit at Sanofi. He holds a B.S. in health care administration from Oregon State University.

Dr. Lloyd Johnston, Ph.D. has been the Chief Operating Officer and Senior Vice President of Research & Development at Selecta Biosciences, Inc. since January 2014. Dr. Johnston served as Senior Vice President of Pharmaceutical Research, Development & Operations at Selecta Biosciences, Inc. from 2011 to 2013. Dr. Johnston served as Vice President of Pharmaceutical Research & Development at Selecta Biosciences, Inc. since July 2008 until 2011. Prior to joining Selecta Biosciences, Dr. Johnston was Vice President of Operations for Alkermes having responsibilities for process development, scale-up and clinical manufacturing for pulmonary and sustained release injectable products as well as leadership of Alkermes 90,000 square foot manufacturing facility in Chelsea, MA. Dr. Johnston was also a Project Leader and member of Steering Committees for numerous products through various stages of development from Phase 1 through registration. Dr. Johnston was an original member of Advanced Inhalation Research (AIR??) Inc., a private company acquired by Alkermes in 1999. Prior to joining AIR, Dr. Johnston was a professor in the Department of Chemical Engineering at the University of New South Wales in Sydney, Australia. He holds a B.S. in Chemical Engineering from Queen's University in Canada and his M.S. and Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.

Dr. John H. Leaman, M.D. has been Chief Financial Officer and Head of Corporate Strategy at Selecta Biosciences, Inc. since October 26, 2017. Dr. Leaman served as the Head of Corporate Development at InfaCare Pharmaceutical Corp. Dr. Leaman served as Chief Financial Officer of Aevi Genomic Medicine, Inc. (formerly, Medgenics, Inc.) from September 16, 2013 to February 9, 2016. Dr. Leaman was a Principal of Devon Park Bioventures. Dr. Leaman has a combination of clinical, strategic and financial expertise derived from his experiences as a physician and biotech and pharmaceutical consultant. Dr. Leaman served as an Associate Principal at McKinsey & Company, where he advised senior management of large biotechnology and pharmaceutical companies on a variety of strategic and operational issues including drug marketing and product launch strategies, drug licensing and overall portfolio management and payor contracting and pricing strategies. He served on the Board of Inotek Pharmaceuticals Corporation. He oversaw the fund's investment and corporate board duties in life science investments including Proteon Therapeutics, Inc., Inotek Pharmaceuticals Corp., ZS Pharma, Inc. and MicuRx Pharmaceuticals, Inc. Dr. Leaman has more than a decade of corporate strategy, finance, venture capital and M&A experience in the life sciences industry. He served as Vice President of Commercial Assessment at Shire plc, with responsibility for the strategic assessment of licensing and M&A opportunities, including Shire's acquisition of SARcode Bioscience. Dr. Leaman received an M.D. from the Perelman School of Medicine and MBA from the Wharton School at the University of Pennsylvania. He received a B.A. in Psychology, Philosophy and Physiology at Oriel College, University of Oxford. Dr. Leaman received a BS in biology from Elizabethtown College.

John Leaman serves as the CFO, Head of Corporate Strategy of Selecta Biosciences. John started at Selecta Biosciences in October of 2017. John is currently based in the Greater Philadelphia Area.